Cardiac
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF).
Study ID: Elevate-HF
Principal Investigator: Puvanalingam Ayyadurai, MD, FACC
Oncology
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cance Whose Tumors Express PD-L1
- Study ID: ARTEMIDE-Lung02
- Principal Investigator: Ivan Bustillo, M.D.
A Phase III Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completel Resected High-Risk Stage I Non-Small Cell Lung Cancer
- Study ID: INTerpath-014
- Principal Investigator: Ivan Bustillo, M.D.
Gynecologic
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Study ID: ECHO
- Principal Investigator: Collette Lessard, MD
- Status: Enrolling
